Pfizer, BioNTech ace long-term test of their COVID vaccine in kids 12 to 15, setting up likely approval

Six months ago, Pfizer and BioNTech secured emergency use authorization for their COVID-19 vaccine in 12- to 15-year-olds. Now, the companies have provided long-term data that could bring a full approval in the age group. In a follow-up study of 2,228 children, the vaccine was 100% effective in preventing infection seven days to four months after the second dose. There were no serious safety concerns observed in those with at least six months of follow-up. With the results, the companies will file for full FDA approval in the age group. In August, the shot won an FDA nod in people 16 and older.